Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)

Terrence F. Blaschke, M.D.

Committees: Joint Nonprescription Drugs Advisory Committee and Endocrinologic

and Metabolic Drugs Advisory Committee Meeting; and, Joint Nonprescription Drugs Advisory Committee and Pulmonary Allergy Drugs Advisory Committee

Meeting

Meeting Dates: January 23-24, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda items (1) new drug application (NDA) 21-887, proposing over-the-counter (OTC) use of Orlistat (tetrahydrolipstatin) 60 milligram (mg) capsules, sponsored by GlaxoSmithKline Consumer Healthcare, L.P., an associate of GlaxoSmithKline PLC, to promote weight loss in overweight adults when used along with a reduced calorie and low fat diet; and, (2) discussions of the continued need for the designation of over-the-counter (OTC) epinephrine-metered dose inhalers (MDIs) for the treatment of asthma as an essential use of ozone-depleting substances under 21 CFR 2.125, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude
Consulting on unrelated matter	Company could be affected by the OTC epinephrine-MDIs discussions	Less than \$10,001 per year
Consulting on unrelated matter	Company that has a financial interest in Orlistat	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

	December 23, 2005
<u>/s/</u>	
Signature of SGE	Date